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ABSTRACT 
 
The liver X receptors (LXRα and LXRβ) are members of the nuclear receptor 
superfamily of ligand activated transcription factors and have functions as 
regulators of lipid and glucose metabolism, as well as inflammatory response. 
In recent years, several reports have demonstrated an important role of LXRs in 
the control of cell proliferation.  
 
In Paper I we demonstrate that LXR activation with synthetic agonist 
GW3965 leads to a strong antiproliferative effect in four different human breast 
cancer cell lines. We show that LXR activation induces an arrest at the G1/S 
check point of the cell cycle with a hypophosphorylation of retinoblastoma 
protein and a downregulation of cell cycle modulators such as Skp2, cyclin A2 
and cyclin D1. We further show that the antiproliferative function of LXRs is 
independent of lipid biosynthesis. 
 
In Paper II we follow up the results in Paper I to elucidate more mechanisms 
of LXR activation in human breast cancer cell lines. Using microarray analysis, 
we find both cell line specific and common LXR target genes. The common 
responsive genes that were upregulated upon LXR activation are annotated to 
known metabolic functions of LXR, while the common downregulated genes 
mostly include those with function in cell cycle regulation and proliferation. 
Comparing the common downregulated gene set, with breast cancer tumour 
samples and patient data we find that patients with tumours expressing lower 
levels of these LXR target genes had better survival compared to patients with 
a higher expression of these genes. In addition, we identify the E2F family of 
transcription factors as mediators of the antiproliferative effect of LXR 
activation. 
 
In Paper III we demonstrate that activation of LXRs with GW3965 decreases 
proliferation in human colorectal cell lines with a cell cycle arrest in the G1 to S 
phase transition. We demonstrate a decreased expression of cell cycle 
promoters such as Skp2, CDK1, CDK2, CDK4, cyclin E, cyclin B1 and c-myc, 
as well as hypophosphorylation of retinoblastoma protein. Moreover, we show 
that LXR deficient mice have an increased proliferation in the colonic crypt 
compared to wild type mice. Also, activation of LXRs with GW3965 reduces 
proliferation in the colonic crypt of wild type mice.  
 
In Paper IV we demonstrate that activation of LXRs dampens the 
inflammatory response by downregulating pro-inflammatory mediators in two 
different mouse models of colitis. In addition, LXR deficient mice have a faster 
and more severe disease progression. We further demonstrate that expression 
of LXR regulated genes is suppressed in colon samples from patients with 
either Crohn’s disease or ulcerative colitis compared to healthy controls. 
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative 
colitis, is associated to increased risk of developing colorectal cancer. The data 
in Paper IV suggests the potential for LXR mediated inhibition of inflammation 
during IBD, thus reducing the risk for developing colorectal cancer. 
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1 INTRODUCTION 
 
1.1 NUCLEAR RECEPTORS AND THE LIVER X RECEPTORS 
 
Liver X receptor α (LXRα) and LXRβ, belong to the nuclear receptor (NR) superfamily 
of ligand activated transcription factors. The NRs are attractive drug targets, thanks to 
their ability to control activity by small hydrophobic molecules and the wide range of 
processes they control. There are several good examples of NRs as drug targets; steroid 
hormones such as oestrogens and progestins have been used as contraceptives for 
decades targeting the oestrogen receptor (ER) and progesterone receptor (PR). ER has 
also been targeted in breast cancer treatment, using tamoxifen therapy. Dexamethasone 
activated the glucocorticoid receptor (GR) and is used for treatment of inflammatory 
diseases, while thiazolidinediones targets the peroxisome proliferator-activated receptor 
(PPAR) γ utilised in type II diabetes. [1, 2] 
 
There are 48 NRs know in humans and 49 in mice, all are evolutionarily related and 
involved in both normal metabolic and developmental processes, as well as disease 
states such as cancer, inflammation, diabetes, obesity and atherosclerosis [3]. The first 
nuclear receptors to be cloned were the GR [4, 5] and ERα [6, 7]. Cloning and further 
studies of subsequent receptors presented a common structure for the NR superfamily 
consisting of five to six domains (A to F) with regions of high sequence homology [8, 
9]. The variable N-terminal region, A/B, usually contains a transcriptional activation 
domain, or activation function 1 (AF-1), while the C region contains the DNA binding 
domain (DBD), including a highly conserved zinc finger motif. The DBD is 
responsible for binding to hormone response elements (HRE) in promoters of target 
genes. The D domain of NRs is poorly conserved and acts as a flexible hinge region 
between the DBD and the multifunctional E domain which contains both a ligand 
binding domain (LBD), the site for receptor dimerisation, and the activation function 2 
(AF-2). Most NRs also contain a highly variable C-terminal F domain with a poorly 
understood function. [1, 2]  
 
The two LXR isoforms were identified independently by several different groups 
during the mid 90’s. LXRα (official gene symbol: NR1H3) was first cloned by Apfel et 
al. (then called RLD-1) [10] and in the lab of David Mangelsdorf [11]. LXRβ (official 
gene symbol: NR1H2) was identified in the lab of Jan-Åke Gustafsson at Karolinska 
Institutet (named OR-1) [12], by Shinar et al. (NER) [13], Song et al. (UR) [14] and 
Seol et al. (RIP-15) [15]. LXRα and LXRβ are encoded by two separate genes, in 
humans, on chromosome 11p11.2 and 19q13.3, respectively, and the expression 
patterns differ between the isoforms. LXRβ is considered to be ubiquitously expressed, 
while LXRα expression seems to be more restricted, with the highest expression in the 
liver, but also in kidney, gall bladder, lung, testes, spleen, intestine, adipose tissue and 
skin [16, 17]. The two LXR isoforms share about 77% amino acid sequence identity in 
both the DBD and LBD.  
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1.1.1 Transcriptional regulation by NRs and LXRs 
 
NRs both positively and negatively regulate transcription through several distinct 
mechanisms, including ligand-dependent transactivation, ligand-independent repression 
and ligand-dependent transrepression, see Figure 1. Most of the NRs bind to DNA as 
homo- or heterodimers, but a subset of receptors binds to DNA as monomers. The latter 
is often an orphan receptor, or a receptor without known ligand, that can regulate 
transcription through changes in receptor expression or posttranscriptional 
modifications. The LXRs form heterodimers with the retinoid X receptor (RXR) and 
the complex binds to LXR response elements (LXREs) which are characterised by 
direct repeats of the consensus sequence AGGTCA separated by four nucleotides 
(DR4) [11]. The permissive LXR-RXR dimer can be activated both by LXR and RXR 
ligands [11]. 
 
 
 
 
Figure 1. Different molecular mechanisms of LXR ligand activation and transrepression. (a) 
Classical transactivation where the unliganded LXR/RXR heterodimer is bound to DNA 
together with a corepressor complex. In response to ligand activation, the corepressor complex 
is exchanged for a coactivator complex and gene transcription can occur. (b) Alternative 
transactivation where methylated and repressed chromatin excludes unliganed LXR from 
binding. After demethylation and ligand activation, LXR/RXR heterodimer is recruited to the 
DNA, and subsequent recruitment of coactivator complex promotes transcription. (c) 
Transrepression where ligand activated LXR is post-translationally modified by the addition of 
a SUMO protein. The SUMOylated LXR docks to coprepressor complex at the promoters of 
inflammatory response genes, inhibiting the degradation of the complex, and inhibits gene 
transcription. Adapted from [18] with permission from the publisher. 
 
 
In the absence of ligand, LXRs are bound to LXREs on the DNA together with a 
corepressor complex, including the silencing mediator for retinoic acid and the thyroid 
hormone receptor (SMRT) and the nuclear receptor corepressor (NCoR) [19]. This 
corepressor complex acts as a strong repressor of target gene transcription, so called 
ligand-independent repression [20, 21]. In the classic mechanism of ligand-dependent 
transactivation, Figure 1a, ligand binds to the receptor heterodimer causing 
conformational changes, allowing for exchange of corepressor to a coactivator 
complex, and the initiation of transcription of target genes. An alternative ligand-
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dependent activation pathway for the LXRs has also been described, Figure 1b, where, 
in contrast to the previous pathway, unliganded LXR is not bound to the DNA [18]. 
 
NRs and LXRs may also negatively modulate transcription by ligand-dependent 
transrepression, Figure 1c, that does not require direct, sequence specific binding to 
DNA. This mechanism, where upon ligand binding LXRs inhibit transcription of target 
genes through protein-protein interactions with coregulatory proteins and transcription 
factors associated to the target site, has been shown to be important in response to 
inflammatory signals [22, 23]. In addition, LXRs have also been shown to be 
posttranslationally modified by phosphorylation [24-26], acetylation [27], 
SUMOylation [23] and O-linked β-N-acetylglucosamineylation [28] affecting the 
transcriptional activity of the receptors. 
 
 
1.1.2 Ligands 
 
NR ligands are small, hydrophobic, lipid-soluble, and vary greatly in characteristics. 
Endogenous NR ligands include various cholesterol derivatives, retinoids, steroid 
hormones, prostaglandins, benzoates and several fatty acids [1]. The ligand specificity 
is determined by the LBD, but some NRs are potentially promiscuous allowing 
molecules with the right stereochemistry to bind into the ligand binding pocket and 
mimic or block binding of the natural ligand. Environmental pollutants, including 
pesticides, and many plant and industrial chemicals have shown potential to disrupt the 
natural activity of NRs in this manner [29]. There are also a number of NRs referred to 
as orphan receptors lacking a known physiological ligand. Some of these NRs might 
still be ligand-dependent, whereas others have been found by structural studies to be 
“true” orphans without the ability to bind ligand and these receptors have a 
constitutively active AF-2 [1]. 
 
The first endogenous ligands for LXRs, identified by Janowski et al. [30], were 
naturally occurring oxysterols, or oxidised cholesterol derivatives, and the most potent 
agonists include 24(S),25-epoxycholesterol, 20(S)-, 22(R)-, 24(S)-, 25-, and 27-
hydroxycholesterol [30, 31]. Theofilopoulos et al. recently also indentified cholic acid 
(3α,7α,12α-trihydroxy-5β-cholan-24-oic acid) as an endogenous brain specific LXR 
ligand [32]. In addition, a wide range of various plant sterols and stanols have been 
shown to activate LXRs [33]. Among the synthetic ligands, GW3965 [34] and 
T0901317 [35] are the two most widely used. The latter has, however, shown potential 
to also activate farnesoid X receptor (FXR) [36],  pregnane X receptor (PXR) [37] and 
retinoic acid receptor-related orphan receptors (RORs) [38]. Neither T0901317 nor 
GW3965 will discriminates between the two LXR isoforms. New synthetic agonists are 
being developed in order to selectively activate specific LXR pathways. LXR-623, 
activates LXRs without inducing hepatic lipogenesis [39]. Isoform specific agonists 
include the LXRβ specific ligands; WYE-672, a partial and tissue-selective agonist 
[40], GW6340, intestine-specific agonist without lipogenic activity [41] and GSK9772, 
selective for LXR mediated transrepression of pro-inflammatory gene expression [42]. 
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In addition, LXR antagonists have also been reported, both synthetic GSK2033 [43] 
and naturally occurring endogenous and plant ligands as reviewed by Viennois et al. 
[33]. 
 
 
1.1.3 LXR regulated pathways 
 
1.1.3.1 Cholesterol metabolism 
 
Cholesterol is crucial for our survival, from being building blocks in cell membranes, 
involved in neural signalling and as precursor of vitamin D, bile acids and steroid 
hormones. The source of cholesterol is both de novo synthesis, primarily in the liver, as 
well as dietary intake. Cholesterol is transported in the body by a group of lipoproteins. 
High-density lipoprotein (HDL) transports cholesterol to the liver for excretion, while 
low-density lipoprotein (LDL) and very low density-lipoprotein (VLDL) transport 
cholesterol from the liver out to peripheral tissues when needed.  
 
Reverse cholesterol transport (RCT) is a process where cholesterol is transported from 
peripheral tissues to the liver where it can be processed and excreted. When cholesterol 
is in excess, it can be bound to pre-HDL particles or apolipoprotein AI (APOAI) with 
the help of sterol transporters of the ATP-binding cassette (ABC) family, and is 
subsequently transported to the liver via the plasma. In the liver, cholesterol is 
converted into bile acids (BAs) that can then be excreted via the bile and the intestine. 
The LXRs are involved in controlling RCT by regulating members of the ABC family. 
Activation of LXR leads to induction of ABCG1 and ABCA1, which in turn promotes 
cholesterol efflux to HDL [44-47]. LXR activation has also been shown to control 
macrophage cholesterol efflux through the joint regulation of apolipoprotein E (ApoE), 
ABCA1 and ABCG1 expression, promoting incorporation of cholesterol into HDL 
particles [48].  
 
LXR activation also affects other members of the ABC family, specifically ABCG5 
and ABCG8, that together with ABCA1 promote sterol excretion into the bile and 
faeces, and limiting cholesterol absorption from the intestine [41, 49]. Intestinal 
activation of LXR by synthetic agonist T091317 also decreases intestinal expression of 
Niemann-Pick C1-like protein 1 (NPC1L1), a vital factor for cholesterol absorption in 
the intestine [50]. NPC1L1 is responsible for absorbing free cholesterol from the 
intestinal lumen into the enterocytes, where it is esterified by acetyl-Coenzyme A 
acetyltransferase 2 (ACAT2) into cholesteryl esters. The cholesterol influx by NPC1L1 
is opposed by the efflux of ABCG5 and ABCG8, pumping cholesterol back into the 
lumen. The importance of the intestine, and not only the liver, in RCT has been further 
highlighted by data from Brunham et al. on the role of intestinal ABCA1 to control 
plasma HDL levels [51, 52]. In addition, Lo Sasso et al. showed how intestinal specific, 
but not hepatic specific, LXRα activation stimulated RCT and decreased intestinal 
cholesterol absorption, by ABCG5/ABCG8 upregulation and NPC1L1 downregulation, 
increased HDL synthesis and reduced ACAT2 activity [53]. 
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The LDL receptor (LDLR) is responsible for taking up LDL-cholesterol from the 
plasma and is tightly regulated by sterol regulatory element binding proteins (SREBPs). 
When cellular cholesterol levels are low, there is an enhanced processing of SREBPs to 
their mature forms, which leads to increased expression of LDLR [54]. The activated 
mature SREBPs will then promote both de novo synthesis and increased uptake of 
cholesterol. Activation of LXRs has been shown to negatively regulate this pathway by 
inducing expression of the inducible degrader of LDLR (IDOL, also known as Mir and 
Mylip), an E3 ubiquitin ligase targeting LDLR for destruction [55]. In addition, 
activation of LXRα also reduces expression of two key enzymes in cholesterol 
synthesis; lanosterol 14α-demethylase (CYP51A1) and squalene synthase [56].  
 
The importance of LXRs in cholesterol homeostasis was discovered by Peet and 
colleagues using LXRα deficient mice (LXRα-/-). The mice appeared normal and 
healthy under a normal low cholesterol diet, but when challenged with a diet high in 
cholesterol, the LXRα-/- mice failed to increase BA synthesis and excretion, leading to 
accumulation of cholesterol esters in their livers. The reason for this was a failure to 
induce gene expression of cholesterol 7α-hydroxylase (Cyp7A1), the rate-limiting 
enzyme in BA synthesis [57]. LXRβ-/- mice, however, maintain their resistance to high 
levels of dietary cholesterol, indicating that LXRα and LXRβ, although similar in 
many aspects, also have separate and unique functions [58, 59]. In contrast to rodents, 
LXR activation in primary human hepatocytes leads to suppression of Cyp7A1 [60, 
61], demonstrating an important species difference upon LXR activation. Kotokorpi et 
al. further studied this interspecies difference through genome wide expression 
profiling of primary hepatocytes from humans and rats. They showed that GW3965 
treatment in human primary hepatocytes, among other effects, leads to suppressed BA 
synthesis, reduced secretion of triglyceride (TG) bound to VLDL and increased lipid 
storage [62]. Wang et al. reported that lipid homeostasis was disturbed also in the brain 
from LXRαβ-/- mice compared to WT mice, with an accumulation of lipid droplets in 
the brain of LXR deficient mice [63]. 
 
The beneficial effects of LXR activation by reducing cholesterol levels and by anti-
inflammatory signalling, discussed more below, suggests the LXRs as important targets 
for atherosclerosis prevention and treatment, and several studies have shown this to be 
true. Synthetic LXR agonists have been demonstrated in several animal models to have 
atheroprotective effects [53, 64-66] and also to reduce platelet aggregation [67].  
 
Alterations in cholesterol homeostasis have also been connected to the initiation and 
development of Alzheimer’s disease and high cholesterol levels constitute a risk factor 
for this disease. Activation of LXRs increases cholesterol efflux and may lead to 
induced secretion of β-amyloid, thereby reducing the risk of amyloid deposition in the 
brain [68, 69]. The LXRs have also been linked to multiple sclerosis (MS) [70] and 
Parkinson’s disease [71], where both cholesterol homeostasis and the anti-
inflammatory functions of LXRs might be of importance. 
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1.1.3.2 Lipid metabolism 
 
Lipids (fatty acids) are synthesised in the liver from acetyl-CoA, and the esterification 
of fatty acids leads to the production of triglycerides; a process referred to as 
lipogenesis. In the liver, LXR activation induces de novo lipogenesis by induction of 
SREBP1c, acetyl CoA carboxylase (ACC), stearoyl-CoA desaturase 1 (SCD1) and 
fatty acid synthase (FAS), thereby increasing triglyceride (TG) content in the liver and 
circulating plasma [35]. TG-rich VLDLs secreted from the liver transport lipids to 
adipose and other peripheral tissues. LXR activation inducews expression of lipid 
transfer proteins, such as cholesterol ester transfer protein (CETP) and phospholipid 
transfer protein (PLTP), as well as lipoprotein lipase (LPL), to help transport TGs to the 
adipose tissue [72-74].  
 
The LXRs also appear to have functions within the adipose tissue; both LXRs are 
highly expressed in adipose tissue, and the expression of LXRα increases during 
adipocyte maturation [75, 76]. LXRs affect expression of genes involved in lipid 
metabolism in adipocytes, but do not seem to influence adipocyte differentiation [77, 
78], however, this issue remains somewhat controversial. Stenson et al. showed that in 
white adipose tissue (WAT) in human and mouse, GW3965 activated LXR promotes 
lipolysis and fatty acid oxidation [79]. In brown adipose tissue (BAT), LXR stimulation 
decreases the expression of uncoupling protein 1 (UCP1), involved in thermogenesis 
and energy expenditure, and reduces energy expenditure [80]. Further, GW3965 
treatment in ob/ob mice, a transgenic mouse model for obesity, altered the fat 
distribution by decreasing visceral fat and inversely increasing the subcutaneous fat 
depot, as well as changing the lipid composition with an overall change towards less 
lipotoxic lipids [81]. 
 
 
1.1.3.3 Glucose metabolism 
 
Beyond the effect on lipid homeostasis, the LXRs also have other vital functions 
connected to glucose metabolism. After eating, circulating glucose levels will 
increases, thus promoting insulin release from the pancreas. Insulin stimulates glucose 
uptake from plasma primarily to muscle and adipose tissue. Insulin also suppresses 
gluconeogenesis in the liver and promotes conversion of glucose into glycogen for 
storage. The insulin-responsive glucose transporter GLUT4 facilitates the glucose 
uptake from plasma to muscle. Within the cell, glucose is converted into glucose-6-
phosphate by hexokinase to be targeted for glycolysis and energy production. Other 
glucose transporters also play a role, including GLUT1 and GLUT2. GLUT1 has a high 
affinity for glucose, thus making it important in tissues with high energy demands, 
while GLUT2 operates as a bidirectional transporter with a low affinity for glucose and 
is expressed in kidney, intestine, liver and pancreas. When circulating glucose levels 
decrease, glucagon is released from the pancreas, stimulating breakdown of stored 
glycogen into glucose, glycogenolysis, in the liver. In addition, glucagon also increases 
glucose production, gluconeogenesis, in the liver, kidney and intestine.  
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Activation of LXR promotes a lowering of circulating glucose levels by increasing the 
expression of transporters GLUT1 and GLUT4 [76, 82] and promotes glucose uptake 
in WAT and BAT [76, 83, 84]. In the liver, LXR activation suppresses expression of 
gluconeogenic enzymes. For example, it downregulates peroxisome proliferator-
activated receptor γ coactivator-1 α (PGC-1), phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase expression and it also induces the expression of 
glucokinase, which promotes use of hepatic glucose [78, 83]. The interspecies 
differences are also apparent in glucose homeostasis, as highlighted by Kotokorpi et al. 
who demonstrated that GW3965 reduces the expression of GLUT2, as well as 
glucokinase (GCK) and liver pyruvate kinase (PKLR), two key glycolytic kinases, in 
human, but not rat hepatocytes. This suggests a risk for high circulating glucose levels, 
hyperglycemia, in humans, but not rodents, after LXR activation in the liver [62]. 
 
Effects of LXR in the pancreas have also been observed. Activation of LXR with 
synthetic agonist increases basal and glucose-induced insulin levels in a human 
pancreatic β-cell line [85] as well as in isolated human islets [86], thereby simulating 
high glucose levels. LXRβ seems to be the dominating isoform in this context, as 
demonstrated by the fact that LXRβ-/- mice show impaired glucose stimulated insulin 
secretion [87]. LXR activation in vivo has also been shown to decrease expression of 
gluconeogenic genes in models of diet-induced obesity and insulin resistance in wild-
type (WT) and LXRβ-/- mice, but not in LXRα-/- mice [88], as well as in insulin 
resistant rats [89] supporting the role of LXRs in glucose tolerance and insulin 
sensitivity. 
 
The close connection between the LXRs and important metabolic processes, has linked 
the receptors to metabolic disorders, for example diabetes. Activation of LXRs leads to 
improved insulin sensitivity and reduced blood glucose levels in animal models of type 
2 diabetes [83, 89, 90] and induces insulin secretion by pancreatic islets [85]. LXRβ 
knockout animals on a high fat diet develop glucose intolerance due to impaired 
glucose-stimulated insulin secretion [87]. LXR activation in murine pancreatic islet β-
cells inhibits proliferation and may induce apoptosis [91, 92]. Moreover, LXR agonists 
augment human islet function by stimulating insulin secretion [86]. Ketterer et al. have 
also reported a common variation within the LXRβ gene in subjects at increased risk 
for type 2 diabetes. The gene variation leads to impaired insulin secretion, which in turn 
might facilitate the development of the type 2 diabetes [93].  
 
 
1.1.3.4 Inflammatory response and immunity 
 
The LXRs have emerged as important regulators of inflammatory gene expression and 
innate immunity in many different cell types including skin, brain, T and B 
lymphocytes, monocytes, macrophages, pancreatic islet cells, muscle, bone, dendritic 
cells and liver (review in [18]). LXRs reduce the induction of classic inflammatory 
gene signalling such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 
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(COX-2), matrix metallopeptidase-9 (MMP-9) and various chemokines in response to 
inflammatory signalling in the form of lipopolysaccharide (LPS), tumor necrosis factor-
α (TNFα) and interleukin-1β (IL-1β) [94-96]. Arginase II, involved in nitric oxide 
inflammatory response, has also been shown to be an anti-inflammatory target for the 
LXRs [97].  
 
In addition, LXRs have been shown to be essential for macrophage survival and 
elimination of invading bacteria in protective immune responses [98-100]. Activation 
with synthetic LXR agonists reduces inflammatory gene expression in macrophages 
[96]. In a contradictory study, LXR-deficient mice and macrophages were shown to be 
more resistant to Leishmania chagasi/infatum infection, suggesting an antimicrobial 
defence distinct from that in wild type mice and macrophages [101] and different from 
other infections where the LXRs seem to have a protective role.  
 
Castrillo et al. have also shown a crosstalk between LXRs and Toll-like receptors 
(TLRs) in the response to viral and bacterial pathogens. Activation of TLRs with 
microbial ligands blocks the induction of LXR target genes in cultured macrophages 
and inhibits cholesterol efflux [102]. In addition, activation of LXRs ameliorated 
disease progression in a mouse model of lupus-like autoimmunity by helping apoptotic 
cell clearance, thereby maintaining immune tolerance [103].  
 
In antigen presenting dendritic cells (DC), a crucial link between the innate and 
adaptive immune responses, there seems to be some divergent data. Some studies show 
that LXRs have an anti-inflammatory role, inhibiting the expression of chemokine 
receptor CCR7 on maturing DCs and their migration to lymph nodes [104]. It has also 
been demonstrated that they interfere with DC maturation and function, as well as DC-
mediated T cell activation [105]. Others have revealed a pro-inflammatory role, where 
activation of LXRs increased expression of markers for DC maturation and promoted T 
cell proliferation; in addition, LXR positive DCs were found in reactive lymph nodes in 
vivo [106].  
 
The role of LXRs as modulators of the immune response has linked the receptors to 
several disease states. As mentioned above, LXRs have been suggested to have a 
protective role against viral and bacterial pathogens, although this remains somewhat 
controversial and needs further exploring. Studies on LXRs in arthritis also reveal 
divergent results, showing both a protective role in rheumatoid arthritis [107, 108] and 
osteoarthritis [109, 110] after LXR activation by downregulation of pro-inflammatory 
mediators, as well as exacerbated progression of rheumatoid arthritis by promoting 
inflammation and cartilage destruction after treatment with synthetic agonists [111, 
112]. 
 
Fowler et al. demonstrated the anti-inflammatory activity of LXRs in both irritant and 
allergic contact models of dermatitis, suggesting that LXR activators could provide a 
new class of therapeutic agents for the treatment of cutaneous inflammatory disorders 
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[113]. Moreover, topical treatment with LXR agonist modulates epidermal 
proliferation, differentiation and permeability barrier function, together with the anti-
inflammatory activity providing a role for LXRs in both cutaneous inflammatory 
disorders and skin disorders [114]. Recently, evidence has also emerged that LXRs are 
involved in melanin production, something that is of importance in pigmentation 
conditions such as vitiligo [115, 116]. LXRs have also been suggested to be involved in 
decreasing cutaneous inflammation associated with the ageing of the skin induced by 
chronic UV radiation [117]. 
 
 
1.2 CANCER 
 
Cancer is a worldwide problem with 12.7 million new cases and 7.6 million deaths 
reported for 2008, with lung, breast, colorectal and stomach cancer being the most 
common  [118]. As the world’s population continues to grow and live longer lives, the 
incidence of cancer is thought to increase to a total of 22.2 million cases by the year 
2030 [119].  
 
A massive amount of research has been conducted to further understand how and why 
cancers develop, but many questions remain. The process of cancer development 
appears to be stepwise, see Figure 2, starting with increased proliferation of normal 
cells and ending with a metastatic tumour with the ability to spread throughout the 
body. The stepwise process demands time and accumulation of mutations and changes. 
The concept of cancer is a collection of many different forms of cancer, each with their 
own characteristics, but some features in common.  Over ten years ago, Hanahan and 
Weinberg, first coined the concept “hallmarks of cancer” in their classic review 
published in Cell [120]. They described six capabilities acquired during the 
development of a tumour in an attempt to better explain the characteristics of disease 
development and progression. The six original hallmarks were: 1) sustaining 
proliferative signalling, 2) evasion of apoptosis, 3) sustained angiogenesis, 4) enabling 
replicative immortality, 5) tissue invasion and metastasis and 6) insensitivity to growth 
suppressors. In the updated version [121], Hanahan and Weinberg also included two 
additional hallmarks; avoiding immune destruction and deregulating cellular energetic, 
and two enabling characteristics; genome instability and mutation, and tumour 
promoting inflammation. These characteristics make it possible for the cancer cell to 
acquire the necessary capabilities and promote tumour progression. The hallmarks as a 
concept are a useful way to organise the necessary characteristics to be obtained and 
possessed by cells at some point in order to generate cancer. However, cancer as a 
system is evolving, dynamic and heterogeneous, so the complexity grows which 
explains the difficulties of finding efficient ways to treat cancer.  
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Figure 2. A model of cancer progression; from a normal cell to a metastatic tumour. Tumour 
progression starts, here illustrated by epithelium cells of the colon, with normal cells that 
acquire mutations (often in tumour suppressor genes) that lead to excessive proliferation, 
hyperplasia, and finally dysplasia. With the help of further mutations, inhibition of tumour 
suppressors and activation of oncogenes, cells will continue to grow and survive, until a 
metastatic tumour is formed, with the ability to invade surrounding tissues and spread 
(metastasise) to the whole body. 
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The cause of cancer is a widely researched area today and many correlations have been 
made from the earliest data with ionising irradiation and carcinogenic chemicals. One 
link that is of interest is the increased risk for some cancers in individuals with excess 
bodyweight, an increasing problem in the world today. The 2007 report from the World 
Cancer Research Fund highlighted the evidence for an association between body 
fatness and increased risk for oesophageal adenocarcinoma and cancers of the 
colorectum, pancreas, breast (after menopause), endometrium and kidney [122]. 
Clinical and epidemiological studies have also linked cancer to chronic medical 
conditions, such as metabolic syndrome and obesity, inflammatory diseases and 
autoimmune conditions [123-125]. 
 
As mentioned above, inflammation has been proposed to be included in the “hallmarks 
of cancer”, suggested as the seventh hallmark [123, 126]. It has been shown that 
chronic inflammatory conditions predispose to various forms of cancer, including 
gastric, lung, colorectal and liver cancer [127-130]. In addition, several clinical studies 
have also shown that long-term treatment with a low dose of non-steroidal anti-
inflammatory drugs (NSAIDs) might reduce incidence and mortality of some cancers  
[131, 132]. There is also a suggested inflammatory component in the tumour 
microenvironment that promotes tumour proliferation and survival. The inflammatory 
microenvironment has also been suggested to contribute to inducing genetic instability, 
an important step in tumour progression [126]. In short, the immune and inflammatory 
mechanisms seem to be connected to all stages of tumour development; helping tumour 
initiation, with increased mutations, genomic instability and epigenetic modification of 
the DNA mismatch repair system; survival of tumour cells, by activation of tissue 
repair systems and inducing proliferation as well as stimulating angiogenesis; and in 
final promotion of metastatic tumours [133]. However, the inflammatory response also 
has initial beneficial effects, killing off developing tumour cells. It is when the tumour 
escapes this defence that the protumorigenic effects of inflammation dominates.  
 
 
1.2.1 Breast cancer 
 
Breast cancer is by far the most commonly diagnosed form of cancer in Swedish 
women, corresponding to 30.3 percent of diagnosed cancers in 2011, or over 8000 
individuals, of which only 45 were male [134]. Globally, an estimated 1.38 million new 
breast cancer cases were diagnosed in 2008 [118]. There are some established factors 
connected with a higher incidence; high age, having given birth to few children, early 
menarche, late menopause, high age at first full-term pregnancy, obesity, alcohol and a 
hereditary component with family history of breast and ovarian cancer. Inherited 
mutations in the tumour suppressor genes BRAC1 and BRAC2 are much discussed, 
and account for 80 percent of inherited breast cancers, or 5-10 percent of all breast 
cancer cases [135]. 
 
Breast cancer is complex and can be considered as a heterogeneous group of different 
diseases, all with different biological features and clinical outcomes. Before molecular 
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profiling, all classifications were made based on morphological observations. Now, 
classifications are based on histological type, tumour grade, lymph node status and 
presence of predictive markers such as ERα, PR and human epidermal growth factor 
receptor 2 (HER2). Nearly all breast cancers are carcinomas, most often originating 
from the mammary ducts, i.e. mammary ductal carcinomas, but also from the lobules 
that supply the milk to the ducts, so called lobular carcinomas. Only in rare cases the 
tumours arise from the connective tissue in the breast, producing breast cancer 
sarcomas. Gene expression profiling has not only contributed to a better understanding 
of the heterogeneity of breast cancer at a molecular level, but it has also lead to new 
classifications that today include five subgroups: luminal A, luminal B, basal-like, 
HER2-enriched and others. The classification is of importance when choosing 
appropriate therapy, the luminal A and luminal B subtypes express ERα and can 
therefore be targeted with endocrine therapy, while trastusumab, a humanised 
monoclonal antibody against HER2, can be used for the HER2-enriched subgroup 
[136, 137]. Another commonly used term is triple-negative breast cancer. This is 
characterised by a lack of ERα, PR and HER2 expression, and is related to the basal-
like subgroup; a majority of basal-like tumours are triple-negative. Patients with triple-
negative tumour have a relatively poor outcome and cannot be targeted with either 
endocrine therapy, or HER2 directed therapies [138].   
 
Early detection and diagnosis, followed by surgical removal of the tumour is still the 
most successful strategy for treatment. Surgical treatment is often combined with 
radiation or chemotherapy to increase survival rate and reduce the risk of metastases. 
Endocrine therapies, mentioned above, with selective oestrogen receptor modulators 
(SERM’s) (tamoxifen and raloxifene), progesterone-like drugs and aromatase inhibitors 
target ERα and/or PR and is are choices for luminal A and B subtypes, but not all 
cancers respond and the therapy may lead to endocrine resistance of the tumour. 
Monoclonal antibodies such as trastusumab and bevacizumab selectively bind to HER2 
and vascular endothelial growth factor (VEGF, important for angiogenesis), 
respectively, and may prevent tumour growth.  
 
 
1.2.2 Colorectal cancer 
 
Colon cancer is the third most common cancer in both men and women in Sweden, 
representing seven percent of reported cases in 2011. Colorectal cancer (CRC), where 
cancer of the rectum and anus also are included, represents ten percent of all reported 
cases, or over  6,300 individuals diagnosed [134]. Worldwide, colorectal cancer takes 
position as the third and second most common form of cancer in men and women 
respectively, with over 1.2 million cases and 608,000 deaths in 2008. Almost 60 
percent of all cases reported occur in developed countries with Australia, New Zealand 
and Western Europe on the top [118]. 
 
Most patients with CRC are above 75 years, only about five percent are under 50 when 
diagnosed [134]. Besides age, a Western lifestyle is often strongly associated with an 
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increased risk of CRC. The incidence is, as mentioned above, higher in developed 
countries, but the risk is now also increasing in less developed countries that adopt a 
more Western lifestyle. Migration studies have shown that immigrants to high-
incidence developed countries increase their risk to develop CRC compared to natives 
that remain in the low-incidence countries. The factors behind the increased risk are, 
however, debated. A diet rich in red meat, fat, carbohydrates and processed foods are 
often associated to an increased risk, while a diet high in fruit, vegetables and fibre 
seems to reduce the risk for CRC. Smoking, high consumption of alcohol, diabetes, 
obesity and lack of physical activity has also in some cases been connected to CRC. 
[139] 
 
Patients with inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s 
disease, account for about two-thirds of the incidence of CRC and the highest risks are 
found in patients with longer disease durations, extensive disease and in patients 
diagnosed before the age of 30 [140, 141]. Preventive colectomy is an option for these 
patients, but today, regular examinations with colonoscopy for early detection of cancer 
is preferred. There is also a hereditary component in some forms of CRC. The Lynch 
syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), and 
familial adenomatous polyposis (FAP) colorectal cancer are the two most common 
hereditary CRCs, occurring in one in 300 and one in 7,000 people affected by CRC 
respectively [142]. 
 
The clinical model of CRC is often divided into four different stages, to better illustrate 
the stepwise and slow progress of the disease development, from normal epithelium to 
adenomatous polyps and invasive carcinomas. Tumours of stage I, which are limited to 
the wall of the colon, and those of stage II, which have begun to grow through the wall 
of the colon, are curable by surgical excision. If left untreated, the cancer will spread to 
the lymph nodes near the tumour, referred to as a stage III tumour. At this stage, 
adjuvant chemotherapy is added to surgical excision with a success rate up to 73%. 
Chemotherapy might also be given after surgery to reduce the risk for relapse. Stage IV 
CRC, where the tumour has grown into adjacent tissues or spread and formed 
metastases, often in the liver, is usually incurable [143]. New therapeutic methods, 
using for instance combinatorial approaches with anti-inflammatory agents, have been 
suggested in order to further increase patient survival. NSAID treatment, more 
specifically with the use of acetylsalicylic acid, seem not only to reduce the risk for 
CRC, but also, when used post-diagnosis, to  reduce the number of distant metastasis 
and increase overall survival [144]. 
 
The molecular basis for the progression of CRC, through the different stages, is not 
fully understood, however certain factors have been suggested to be required to initiate 
and drive the progression of the tumour. Dysregulation of the Wnt signalling pathway, 
through inactivation of the adenomatous polyposis coli (APC) gene or activation of  β-
catenin, is considered to be the initiating event in CRC, leading to a constitutively 
active Wnt signalling pathway and induction of a number of cell proliferation and 
survival genes [145, 146]. It is germ line mutations of APC that give rise to FAP 
 14 
syndrome, and a high risk for early onset CRC [147]. Tumour progression is then 
furthered by genomic instability, such as chromosomal instability, with an allelic 
imbalance at several chromosomal loci, chromosome amplification and translocation, 
or by defects in the DNA mismatch-repair system, as for patients with HNPCC. Several 
factors contribute to progression from adenomas into tumour. These include alterations 
of tumour suppressing pathways, such as transforming growth factor β (TGFβ), BCL2-
associated X protein (BAX) and the p53 pathway, but also activation of oncogene 
pathways, such as RAS and BRAF, as well as phosphatidylinositide 3-kinase (PI3K) 
[143]. 
 
 
 
 
Figure 3. The structure of the colon (illustrated with a tissue section from mouse) including: 
Muscularis externa, an outer muscle layer responsible for the motility of the content in the 
lumen. Submucosa, a layer of connective tissue connecting the muscularis externa to the 
mucosa. The mucosa, or the inner layer of the colon, include a layer of surface epithelial cells, 
lamina propria (connective tissue) and an outer layer of muscle (lamina muscularis mucosae).  
In the colonic crypt, stem cells are found at the bottom, followed by a section with transit cells 
and finally a section with differentiated cells. The larger mucus secreting Goblet cells can also 
be seen in the colonic crypt.  
 
 
The structure of the colon can be seen in Figure 3, illustrating how the colonic crypt is 
made up of different sections. A stem cell population, also known as crypt base 
columnar cells, resides at the bottom of the crypt. The stem cells produce progenitor 
cells, also called transit amplifying cells, which differentiate and migrate up the crypt to 
the crypt collar. At the top of the crypt, cells undergo apoptosis and are released into 
the lumen, a process referred to as cell shedding [148]. The whole process takes two to 
three days, making the intestinal epithelium the most rapidly regenerating tissue in the 
body. The various differentiated cell types of the crypt include enterocytes (or intestinal 
absorptive cells), mucus secreting Goblet cells, hormone-secreting enteroendocrine 
cells and Paneth cells. The latter are attributed a variety of roles, including secretion of 
antimicrobial products [149].  
 
The stem cell population of the crypt is of special interest when discussing CRC, and is 
defined by two specific functional properties: self-renewal and multipotency. This 
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means that these cells have the ability to both continue dividing over a long time and to 
produce cells of any type specific to the colon. These two characteristics are also 
suspected to be of importance for cancer stem cells [150, 151]. In addition, the Wnt 
signalling pathway is crucial for both normal colon stem cell activity and CRC 
initiation. However, studies have indicated that the levels of active β-catenin differ 
between tumour cells in a population. To explain this, a model has emerged with a 
mixed tumour population of “normal” differentiated tumour cells and CRC stem cells. 
The CRC stem cells are thought to contain the tumourigenic capacity, with altered Wnt 
activity, self-renewal ability and the multipotency of stem cells [152]. 
 
One of the major risk factors for CRC is, as mentioned, IBD, and it is believed that 
the interaction between the colonic epithelial cells and macrophages, neutrophils and 
other inflammatory cells plays an important role in the tumour development. The 
inflammatory state leads to an overproduction of reactive oxygen and nitrogen 
species and an upregulation of several inflammatory genes and growth factors in the 
mucosa of the colon, resulting in DNA damages, as well as an increased epithelial 
cell turnover and further tumour progression. [153]  
 
 
1.2.3 The cell cycle and cancer 
 
The topic of the cell cycle is extensive and there is too much information on how cells 
manage division and proliferation to go into any depth in this thesis. This chapter is 
therefore focused on giving a brief summary of the concept of the cell cycle in 
eukaryotic cells. It will also connect the cell cycle to the uncontrolled cell proliferation 
seen in cancer in order to help discussions in later chapters. 
 
The cell cycle has two main objectives. First, during the interphase period, the cell has 
to grow, duplicate its chromosomes and prepare for the second objective, mitosis, 
where the cell divides into two distinct cells, a pair of daughter cells. The cell cycle is 
often divided into four phases (see Figure 4); gap 1 (G1) phase, synthesis or S phase, 
gap 2 (G2) phase and finally mitosis, or M phase. In addition, the cell might leave the 
cell cycle and go into the quiescent gap 0 (G0) phase, or the resting non-dividing phase. 
Specific checkpoints, or restriction points, exists for each phase to check if all 
necessary processes have been completed and the cell is ready to proceed to the next 
phase. The cell cycle might also be arrested due to external signals, such as in response 
to stress from DNA damage or lack of nutrients. Many players are involved in 
controlling these checkpoints, preventing DNA damages to be transferred into daughter 
cells as well as uninhibited proliferation of tumours [154]. 
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Figure 4. Schematic illustration of the cell cycle, divided into four phases G1 (gap 1, the first 
growth phase), S (synthesis, DNA replication), G2 (gap 2, second growth phase and 
preparation for mitosis), and M (mitosis). Non-dividing cells enter G0 (gap 0, resting phase). 
Progression through the cell cycle is controlled at several checkpoints, and key regulators 
include cyclins, CDKs, CKIs, and RB protein (see text for more details). 
 
 
Two groups of molecules central in the cell cycle are cyclins and cyclin-dependent 
kinases (CDKs). Together cyclins and CDKs form active complexes, with cyclins as 
the regulatory subunits and CDKs as the catalytic subunits, only active when bound to 
its specific cyclin. In G1 phase, the entry and progression of the cell cycle is controlled 
by cyclin D1 and D2, bound to CDK4, CDK5 and CDK6. CDK2 needs to be bound to 
cyclin E in order for the cell to complete the G1/S checkpoint and continue into S 
phase. The cyclin/CDK complexes phosphorylate retinoblastoma protein (RB) and 
inhibit the binding of RB to transcription factors needed for cell proliferation. In S 
phase, cyclin A bound to CDK2 or CDK1 will stimulates DNA duplication and 
regulates the start of the mitotic process. Another group of CDKs, namely CDK7 to 
CDK9 are also important during this phase. These CDKs have two distinct roles, first 
they phosphorylate and activate other CDKs (giving them the name CDK-activating 
kinases, or CAKs), and secondly they form a subunit of a transcriptional complex. 
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During the G2 phase, cyclin B will binds to CDK1 (also called cdc2) and help the 
progression into mitosis [155]. 
 
Besides the CAKs mentioned, there are also other regulators of the CDKs, specifically 
two families of CDK inhibitors (CKIs). The INK4 (inhibitor of kinase 4) family, 
including p15, p16, p18 and p19, inhibit the binding of cyclin D to CDK4 and CDK6, 
whereas the KIP (kinase inhibitory protein) family, p21, p27 and p53, act by binding to 
CDK2. Other CDK modifiers include Cdc25 phosphatase and Wee1 kinase, the latter 
phosphorylates inhibitory sites on CDKs while the former removes these inhibitory 
phosphorylations [155, 156].  
 
In addition, the cell cycle is controlled by the levels of the various cyclins, since the 
CDKs are only active when bound to their specific cyclin. The concentrations of the 
cyclins vary throughout the cell cycle, thereby controlling its progression. Cyclin E is 
expressed mid to late G1 and peaks during the G1/S transition, cyclin A is expressed 
during G2 phase, and cyclin B is expressed from late S and G2, but remains inactive 
until peak concentration is reached during late G2 phase. The levels of D-type cyclins 
are, however, kept relatively constant throughout the cell cycle. [157] 
 
The levels of cyclins and CKIs are controlled by the ubiquitin-mediated proteasome 
system (UPS) that ubiquitiates and targets the proteins for degradation. The UPS 
pathway consists of three steps. First the ubiquitin protein (Ub) is transferred to the 
ubiquitin-activating enzyme, E1, and is activated by hydrolysis of ATP, after which it is 
transferred to the ubiquitin-conjugating enzyme, E2. In the final step, the ubiquitin 
ligase, E3, covalently attaches the Ub to the target protein. Poly-ubiquitinated proteins 
are often targeted for degradation by the proteasome, but other types of ubiquitinylation 
events exist. There are many types of E3 ligases in humans, involved in many different 
biological processes. Two important E3 ligases concerning the cell cycle are the 
anaphase-promoting (APC) complex and the Skp1-Cullin-F-box protein (SCF) 
complex, responsible for the ubiquitinylation of cyclins and CKIs [158].  
 
Deregulation of the control of the cell cycle is a fundamental aspect in tumour 
development, as discussed at the beginning of this chapter; therefore it is not surprising 
that many regulators of the cell cycle have been found to be mutated in various types of 
cancer. Changes include loss of CKIs and RB expression, as well as overexpression of 
cyclins and CDKs, thereby enabling cell cycle progression without the normal strict 
regulatory steps [156]. Many alterations in the APC and SCF complexes are also 
reported, linking UPS to tumour progression. An example is mutations in F-box and 
WD-40 domain protein 7 (FBW7), an SCF E3 ligase that is responsible for targeting 
several oncoproteins for degradation; including cyclin E, Myc, Jun, Notch1 and Notch 
4 [158]. 
 
Decreased protein expression of p27, a CKI from the KIP family, is frequently found in 
multiple human cancers and is often correlated to a poor prognosis. However, 
mutations of p27 are rare, and the decreased expression is thought to be connected with 
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an increased degradation especially by S-phase kinase-associated protein 2 (Skp2), 
identified as the SCF E3 ligase that targets p27 for ubiquitinylation and degradation. 
[159]. Skp2 also has other targets, including cyclin E, p57, p21 and the transcription 
factor E2F1. The importance and prognostic significance of overexpression of Skp2 in 
cancer, both with and without inverse correlations with p27 levels, has been seen in 
numerous studies, as reviewed by Hershko [160]. Skp2 is also believed to have a role in 
the regulation of the SCF complex itself, by being targeted by the APC complex for 
degradation [161]. A recent study also showed the importance of Skp2 in activating 
Akt kinases, helping tumour cells to use aerobic glycolysis in order to manage their 
increased energy needs, a process known as the Warburg effect. The study further 
showed that Skp2 deficiency could sensitise breast cancer tumours to specific 
treatment, showing a clinical value in targeting Skp2. [162]  
 
RB is linked to cancer in several ways; the classic role of RB is as regulator of the G1/S 
checkpoint, as mentioned above. RB is inactivated by phosphorylation, leading to the 
release of bound members of the E2F family of transcription regulators, and the cell 
cycle may proceed. RB has also been appointed other functions, such as preservation of 
chromosomal stability, induction and maintenance of senescence, regulation of 
apoptosis, cellular differentiation, and angiogenesis, and inactivation of mutations in 
several members of the RB family have been found in a range of tumours [163]. 
  
Another key player in tumour progression is p53, found to be mutated or functionally 
inactive in most human cancers [164]. p53 has many functions in the cell, but in view 
of the cell cycle p53 activation, in response to DNA damage, actives CKI p21 and 
inhibits the formation of the cyclin E/CDK2 complex required for G1 to S phase 
progression [165]. Other processes that p53 affects include apoptosis, genomic 
instability, and inhibition of angiogenesis, all of which lead to tumour progression if 
p53 is mutated or inactivated. 
 
 
1.3 THE LIVER X RECEPTORS AND CANCER 
 
Publications linking LXRs to changes in proliferation and cancer have increased 
substantially during the last few years, showing that LXR agonists suppress 
proliferation in a wide range of cancer cell lines, including prostate, breast, colon, 
ovarian and leukaemia cells, and conversely, that LXR deficiency in mice will results 
in increased proliferation. Several mechanisms have been suggested behind the 
antiproliferative effects; direct regulation of the cell cycle, induction of apoptotic 
pathways, changes in cholesterol homeostasis and interrupted hormone-dependent 
proliferation. 
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1.3.1 LXRs and effects on the cell cycle 
 
Fukuchi et al. demonstrated that activation of LXRs with synthetic agonist T0901317 
reduces proliferation of LNCaP human prostate cancer cells both in vitro and in a 
xenograft model, as well as in other human prostate and breast cancer cell lines. Protein 
levels of cell cycle dependent inhibitor p27 were increased and Skp2, a SCF E3 ligase 
mediating degradation of p27 decreased [166]. Suppressed levels of Skp2 and increased 
levels of p27 were also seen in vascular smooth muscle cells (VSMC) treated with 
synthetic LXR agonists. T0901317 and GW3965 inhibited cell cycle progression from 
G1 to S by altering the phosphorylation status of RB at the G1/S checkpoint and this 
effect could be abolished by overexpression of Skp2 [66]. The antiproliferative effect 
of T0901317 was further shown in several human cell lines, including multiple prostate 
and breast cancer cell lines, as well as non-small lung cancer, osteoblastic, squamous 
carcinoma, cervical cancer, gastric cancer and hepatoma cells. In contrast, HEK293, 
transformed human embryonic kidney cells, and Wi38, human diploid fibroblast cells, 
seem to be more resistant to T0901317 [167, 168]. The T0901317 effect on PC3 
prostate cancer cells seems to be unclear, with studies both showing reduced 
proliferation and no effect [166, 168, 169]. LXRs have by Geyeregger et al. been 
shown to be active in leukemic T and B lymphocytes and activation with agonists 
T0901317 or GW3965 inhibited T cell proliferation and cell cycle progression with a 
G1 to S phase arrest. Moreover, the LXR activation also promoted apoptosis in B cells 
isolated from patients with chronic lymphoblastic leukaemia (CLL) [170]. 
 
Data from pancreatic cells seem to be somewhat conflicting. Although Wente et al. 
could not see any changes in proliferation after T0901317 treatment of insulin secreting 
MIN6 cells, a mouse pancreatic islet β-cell line, they reported an antiproliferative effect 
when activating both LXR and RXR in these cells. The dual LXR/RXR activation 
increased expression of both tumour suppressor Smad3 and caspase activity in MIN6 
cells and isolated rat pancreatic islets, suggesting increased apoptosis, but no change in 
Skp2 level was observed [171]. Short thereafter, another group reported that LXR 
activation alone promoted lipid accumulation, lipotoxicity and increased β-cell 
apoptosis in INS-1, a rat insulinoma cell line, and isolated rat pancreatic islets [92]. In 
addition, Meng et al. demonstrated that LXR activation with T0901317 in MIN6 and 
the hamster islet β-cell line HIT-T15 inhibited cell proliferation through a G1 to S cell 
cycle arrest by down-regulating Skp2 mRNA expression and upregulating p27 protein 
levels. The importance of p27 was further highlighted when siRNA knockdown of p27 
partially reversed the antiproliferative effect seen in MIN6 cells [91]. The same group 
further showed that LXR activation with T0901317 results in lipid accumulation and 
lipotoxicity in pancreatic β-cells, via induction of SREBP1c [172], supporting the 
initial study. 
 
In a recent study, Lo Sasso and colleagues demonstrated that activation of either LXRα 
or LXRβ with GW3965 resulted in G1/G0 cell cycle arrest and increased apoptosis in 
human CRC cell lines. Skp2 and cyclin D1 mRNA and protein levels were decreased, 
while p27 protein levels increased. Activation of LXRα was also shown to slow down 
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the growth and induce apoptosis of xenograft tumours in mice [173]. Besides the 
studies already mentioned, reduced Skp2 expression after LXR activation with 
T0901317 has also been seen in human non-small lung cancer, hepatoma and cervical 
cancer cell lines [169]. The effects on p27 protein levels are somewhat inconclusive. 
Some studies have shown an accumulation of p27 protein, often accompanied by Skp2 
downregulation, while others observe the antiproliferative effect of LXRs without 
changes in p27 levels [170, 174]. In addition, Pascual-García et al. showed that the 
antiproliferative effect still remained in p27 deficient macrophages. Instead they 
focused instead on other changes in the cell cycle, namely reduced protein expression 
of cyclin D1 and cyclin B1, as well as CDK2 and CDK4 after LXR activation. 
Although cyclin B1 is involved in later stages of the cell cycle, the effect of LXR 
activation appears to influence G1 to S progression, suggesting that the effects on cyclin 
B1 are secondary [175]. Other effects on cyclins and CDKs have also been reported, 
such as on cyclin B [170, 175, 176], cyclin D1 [66, 173-175], cyclin A [66, 168, 174], 
cyclin E [176, 177], CDK1 [176], CDK2 [175, 176] and CDK4 [175], demonstrating 
the clear influence of LXRs on the cell cycle.  
 
The antiproliferative effect of LXR activation has also been suggested to be linked to a 
key mediator in Wnt signalling, β-catenin, in colon cancer cell line HCT116 [178]. The 
Wnt signalling pathway controls cell to cell communication needed for appropriate cell 
proliferation and differentiation during development and healing. Treatment with 
T0901317 suppressed β-catenin transactivation activity and downregulated mRNA 
expression of some β-catenin target genes, Myc, Bmp4 and MMP7 [178]. 
Dysregulation of Wnt signalling, leading to accumulation of β-catenin, has also been 
reported in human CRC [145, 146], and other NRs, particularly androgen receptor 
(AR), have been shown to modulate the Wnt/β-catenin pathway [179]. 
 
 
1.3.2 LXRs and antiproliferative effects of cholesterol homeostasis 
 
The initial studies by Fukuchi et al. and others also showed that LXR target gene 
ABCA1 expression was connected to reduced proliferation of LNCaP cells. While 
ABCA1 knockdown increased the rate of proliferation, activation of LXRs, and thus 
increased ABCA1 expression, resulted in reduced proliferation [166, 180]. The 
mechanism behind this effect was suggested to involve cholesterol homeostasis. The 
activation of LXRs stimulates cholesterol efflux, which deprives the cancer cell 
membranes of lipids essential for their growth and thereby prevents further growth. 
Transino et al. showed that LXRβ, and not LXRα, is the major regulator of both 
ABCA1 and ABCG1 mRNA expression levels in prostate cancer cell lines [181], while 
Pommier et al. showed that T0901317 treatment leads to upregulation of ABCG1 only, 
in LNCaP cells in vitro and in vivo. The latter study further demonstrated that the 
increased cholesterol efflux, due to LXR activation, resulted in downregulation of the 
AKT survival pathway and induced apoptosis in LNCaP cells [182]. An in vivo study 
from the same lab using LXR deficient mice, showed that LXRs also regulate 
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proliferation in epithelial cells from the dorsal prostate by modulating cholesterol 
homeostasis and the AKT survival pathway  [183], supporting the initial findings. 
 
Lo Sasso and colleagues further highlighted the connection between cholesterol 
homeostasis, cell proliferation and LXRs by using a mouse model of partial 
hepatectomy (PH) [184]. In PH, part of the liver is removed in order to study the ability 
of the liver to regenerate. The cholesterol content in the liver increased after the 
procedure to meet the increasing demands for regeneration and, at the same time, a 
suppression of pathways involving LXR could be seen due to lower levels of 
oxysterols. Activating LXRs with GW3965 reduced the proliferation of the 
hepatocytes, thereby reducing the rate of liver regeneration. Scoles et al. showed 
cholesterol related proliferation also in ovarian cancer cells, where oxidised LDL 
cholesterol stimulated ovarian cancer cells to proliferate and LXR activation with 
T0901317 increased cholesterol efflux, reduced expression of proinflammatory 
cytokines and inhibited proliferation [185]. LDL cholesterol is also needed for 
glioblastoma proliferation, one of the most common forms of malignant primary brain 
tumours, as shown by Guo and colleagues [186]. Treatment with GW3965 resulted in 
dose-dependent inhibition of proliferation and induction of tumour cell death due to 
lower levels of available cholesterol in vitro and in an in vivo xenograft model. Both 
increased cholesterol efflux by overexpression of ABCA1 and reduced cholesterol 
influx was demonstrated as mechanism behind the antitumour effects seen.  
 
A recent study also demonstrated a clear link between LXRs and CRC. Intestinal 
specific LXRα activation was shown to reduce intestinal tumour number and size in 
two different in vivo mouse CRC models, one chemically inducible and one genetic  
[173]. By comparing data from three different in vivo tumour models, the group further 
demonstrated that intestinal specific LXRα activation induced antitumour effects 
through increased cholesterol efflux.  
 
 
1.3.3 LXRs and hormone dependent proliferation 
 
It is widely known that certain hormones and hormone regulated NRs are vital for 
normal cell growth, as well as aberrant growth in some types of cancer. The most well 
known examples are probably the connection between ER and breast cancer, or AR and 
prostate cancer. It appears that there is a cross-talk between LXRs and other NRs, 
possibly through competition for coactivators [187, 188], that link LXRs to hormone 
dependent cell growth. 
 
Androgens are important both for normal prostate cell growth and development, as well 
as during prostate cancer. Chuu et al. showed that LXR agonist T0901317 delayed 
progression from androgen-dependent to androgen-independent tumours [189]. 
T0901317 might act as an AR antagonist in prostate cancer cell lines competing with 
androgen for binding to AR [190]. T0901317 also represses AR activity by 
upregulating sulfotransferase enzyme SULT2A1 and downregulating steroid sulfatase. 
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The first reaction deactivates androgens and the second one reverses this process. These 
changes result in lowered levels of circulating androgens in vivo, inhibited androgen-
dependent prostate regeneration and decreased prostate cancer cell growth [191].  
 
In studies on LXR deficient mice, Kim et al. demonstrated that both LXRα and LXRβ 
are expressed in the mouse ventral prostate, one of the four lobes of the murine 
prostate. LXRα-/- mice, and also to a lesser extent LXRαβ-/- mice, developed symptoms 
of benign prostatic hyperplasia of the ventral prostate [192]; this was supported by later 
studies showing that LXRα is the dominant isoform in AR regulation [193]. A study by 
Dufour et al. showed that LXRs also regulate proliferation in epithelial cells from the 
dorsal prostate, a lobe more similar to the human peripherial zone where most prostate 
cancers originate [183]. 
 
The cross-talk between LXRs and AR was further investigated by Krycer et al. as a 
mechanism in cholesterol homeostasis and prostate cancer [194]. They showed that AR 
antagonises LXR, potentially via competition for coactivators. Consequently, AR 
activation leads to LXR downregulation and reduced cholesterol efflux. High 
cholesterol levels are observed in both the ageing prostate and prostate cancer, and in 
addition epidemiological studies have associated high circulating cholesterol levels 
with an increased risk for prostate cancer, while cholesterol-lowering drugs reduced the 
risk [195].  
 
Krycer et al. and others have also shown cross-talk between LXR and other NRs 
besides AR, such as ER, PR and GR, something that has been supported by both 
studies on LXR deficient mice and treatment with LXR ligands. Gabbi et al. showed 
that LXRβ-/- female mice, but neither LXRα-/- nor LXRαβ-/- female mice, or LXRβ-/- 
male mice develop inflammation and cancerous changes in the gallbladder in an 
oestrogen-dependent manner [196]. Activation of LXR has also been shown to control 
oestrogen homeostasis regulating hepatic oestrogen sulfotransferase (EST or 
SULT1E1), an enzyme responsible for the sulfurylation of oestrogen and other steroids 
[197]. The study additionally showed that LXR activation inhibited oestrogen-
dependent breast cancer cell growth in a mouse xenograft model. 
 
In studies on breast cancer cell lines and tissue biopsies, Vigushin et al. showed that 
LXRα mRNA is expressed in both normal human breast tissue and primary breast 
carcinomas, but to a lower extent in the latter samples. However, the LXRα expression 
in the tumour samples could not be correlated to ER or PR status, nor to patient age or 
tumour size. The group further described that LXR activation inhibited proliferation of 
both ERα positive and negative breast cancer cell lines [198], something that has also 
been shown by several other groups [166, 167]. 
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1.3.4 LXRs and cancer immunology 
 
Avoiding the immune surveillance is one of the hallmarks of cancer and an important 
characteristic of tumour cells and the advance of tumour growth and metastasis [133]. 
Growing tumours release immunogenic material from dead or dying tumour cells, 
thereby engaging tumour-associated DCs to collect this debris. The DCs thereafter 
migrate to tumour-draining lymph nodes and activate naive T and B cells, thus starting 
an immune response against the tumour. Villablanca et al. reported a new role for 
LXRs in cancer biology, namely to prevent this antitumour response from the immune 
system. Tumours can produce oxysterol LXR agonists that can inhibit the expression of 
CCR7 on the DCs. CCR7 is a chemokine receptor critical for the migration of DCs to 
the tumour-draining lymph nodes. The inhibition of CCR7 expression by LXR 
activation consequently dampens the immune response. Treatment with 
sulfotransferase 2B1b (SULT2B1b), an enzyme that sulfurylates cholesterol, decreased 
the availability of LXR ligands and increased the antitumour immune responses [104].  
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2 AIMS OF THE THESIS 
 
The major aim of this thesis is to investigate the role of LXRs in breast and colorectal 
cancer and the underlying mechanisms. Specific aims are to investigate: 
 
 
• the molecular mechanisms behind the antiproliferative effect of LXRs and in 
human breast and colorectal cancer cell lines (Papers I, II and III) 
 
• the correlation between LXR-responsive genes in human breast cancer cells 
and gene profiles associated with the survival of breast cancer patients  
(Paper II) 
 
• the role of LXRs in proliferation of colonic epithelial cells in vivo in mice 
(Paper III) 
 
• the anti-inflammatory role of LXRs in the colon using DSS and TNBS 
induced colitis in mice (Paper IV) 
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3 METHODOLOGICAL CONSIDERATIONS 
 
Materials and methods are described in each paper included in this thesis, but this 
chapter aims to highlight specific aspects about some of the methods used. Only a 
general discussion is included here, more details are described below for each paper. 
 
 
3.1 CELL LINES 
 
Several different immortalised cell lines from various tissues have been used in this 
thesis. The cell lines represent an excellent in vitro model system, being easy to grow, 
manage and manipulate, creating a reliable pool of samples with a high degree of 
homogeneity. Even though the use of cell lines can be considered as standard 
laboratory practice, there are caveats in using these model systems, in particular when 
trying to translate results from in vitro cell line experiments to in vivo situations.  
 
An illustration of one of the problems using cell lines, and the variation in data between 
laboratories, can be seen in the classic experiment from Osborne and colleagues from 
the 1980’s [199] where they compared one of the most widely used human breast 
cancer cell lines, MCF-7, from four different laboratories. The data showed that the 
MCF-7 lines differed in amounts of ER and PR, important markers in breast cancer, as 
well as having different growth rates, response to oestrogen treatment, tumorigenicity 
in mice and chromosomal alterations. It was even found that one of the lines was 
derived from an entirely different patient.  
 
A review in Breast Cancer Research [200] highlights many important concerns using 
cell lines, with the focus on breast cancer cell lines. Issues being raised include “false” 
cell lines or cell lines contaminated with HeLa cells [201] and that many of the most 
frequently used breast cancer lines used are derived from tumour metastases, and not 
from primary tumours, thereby representing late-stage disease. The clonogenicity of the 
cell lines with continuous culturing also leads to a phenotypic and genotypic drift from 
the original cell population. 
 
One additional major disadvantage in using cell lines is the lack of interaction between 
the tumour cell and the environment. The microenvironment of a tumour cell in vivo 
will has a strong influence on growth and survival of the tumour, which is lacking in 
vitro. Xenograft mouse models are an option to simulate a more natural environment, 
but it means going from the convenience and controllability of in vitro studies. 
 
The intention has been to address limitations using cell lines throughout  the work in 
this thesis. Several different cell lines have, when possible, been used as model systems 
for breast and colorectal cancer. Limits have also been put to how many passages cells 
were allowed to undergo before a new stock of cells has to be used, in order to maintain 
the homogeneity of the culture. Other model systems, such as primary cultures are a 
 26 
good alternative, but the ease and convenience of the cell lines make them hard to 
replace. 
 
 
3.2 PROLIFERATION ASSAYS 
 
Several different types of proliferation assays have been performed throughout this 
thesis, all with specific advantages and limitations.  
 
The simplest method used in this thesis is viable cell count using a vital cell stain, 
trypan blue, that selectively stains dead or dying cells with disrupted cell membranes. 
Both stained and non-stained cells are counted in a haemocytometer and the percentage 
of viable cells may be calculated. To see effects on proliferation with this method, a 
time course needs to be set up and changes in absolute numbers of viable cells 
examined. This is a cheap and easy, but somewhat time consuming, method where the 
biggest drawback is that it only gives changes in absolute cell numbers, and no 
information about of the cell cycle status of the cells. 
 
By using a flow cytometry based proliferation assay with a DNA stain, such as 
propidium iodide (PI), it is possible to get a snapshot of the cell population and 
determine which cell cycle phases the cells reside in. It also gives an indication if the 
treatment in question might be toxic to the cells. Additional stainings can be added to 
examine apoptosis, viability and other characteristics of the cells. 
 
5-bromo-2'-deoxyuridine (BrdU) incorporation assays have been used in this thesis 
both in vitro and in vivo. It is based on the fact that BrdU is a structural analog to 
thymidine, allowing it to be incorporated in newly synthesised DNA. The amount of 
incorporation of BrdU thus corresponds to the amount of cells going through S phase. 
We have measured BrdU incorporation both by immunohistochemistry (IHC) on tissue 
sections and by flow cytometry together with PI staining on fixed cells. Using BrdU 
and PI staining together makes it easier to identify changes in the cell population going 
through S phase. 
 
In addition to BrdU incorporation, tissue sections were also, using IHC, stained for 
proliferation marker Ki67. Ki67 is strictly associated with cell proliferation and the 
protein is expressed during all active cell cycle phases, but not in resting cells in G0 
[202]. 
 
 
3.3 MESSENGER RNA AND PROTEIN ANALYSIS 
 
Quantitative polymerase chain reaction (qPCR, real-time PCR) was used to measure 
mRNA expression levels. It is a widely used, specific and sensitive method, but 
nonetheless limitations exist. Good housekeeping, or reference, genes are required to 
normalise data, as well as well designed and gene specific primers. All primers used in 
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this thesis have been carefully tested with dissociation curve analysis in order to detect 
unspecific binding and primer dimers, and changes in housekeeping genes due to 
treatments etc. have been monitored to avoid false results. qPCR analysis needs to be 
complemented with analysis of protein levels and activity. 
  
Protein levels have been measured in this thesis using Western blot, where the two 
major problems are antibody specificity and determination of signal intensity. The first 
problem is hard to address, new antibodies should be tested against negative or positive 
controls if possible, and antibody dilutions and incubation times optimised. There are 
several different methods for quantifying Western blot results, both by analysing band 
density from photographic films (see below) and using newer, possibly more accurate, 
detection methods utilising CCD cameras and digital imaging systems, or by using 
fluorescent secondary antibodies. 
 
Within this thesis, enhanced chemiluminescent horse radish peroxidase (HRP)-linked 
secondary antibodies were used with detection detection by photographic film. For 
quantification, films were scanned and band density analysed using ImageJ 1.43u 
software (Wayne Rasband, National Institutes of Health, USA) according to online 
protocol from Luke Mille [203] and normalised against a loading control. Even though 
care was taken to avoid problems such as saturated films, this is still a significant 
problem when using photographic film, and needs to be considered when evaluating the 
results. 
 
Another way to measure protein levels included in this thesis is enzyme-linked 
immunosorbent assay (ELISA), used in Paper IV. This method still uses antibody 
technology to recognise target protein, but the detection is connected to intensity of 
transmitted light by spectrophotometry. The ELISA is usually performed in plate 
format, making it possible to measure a larger number of samples simultaneously. 
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4 RESULTS 
 
4.1 PAPER I: THE OXYSTEROL RECEPTOR LXR INHIBITS 
PROLIFERATION OF HUMAN BREAST CANCER CELLS 
 
LXR has been shown to be antiproliferative in several cell types and in Paper I, the aim 
was to investigate the role that LXRs might have in human breast cancer cell lines. The 
study was done using four different cell lines; MCF-7 and T47D, both of a luminal 
subtype expressing ERα and PR but not HER2, MDA-MB-231, a basal triple negative 
cell line, and SKBR3, a luminal HER2-enriched cell line lacking ERα and PR 
expression [204]. All four cell lines showed expression of both LXRα and LXRβ, and 
activation with synthetic LXR agonist induced classical LXR target genes, 
demonstrating functional LXR pathways. 
 
We further showed, using a flow cytometry bromodeoxyuridine (BrdU) incorporation 
assay, that synthetic LXR agonists, both GW3965 and T0901315, had an 
antiproliferative effect on all four cell lines. The cells appear to accumulate in G1 and 
G0 cell cycle phases, indicating that LXR activation leads to an arrest at the G1 to S cell 
cycle phase transition. The effect was boosted by reducing the initial rate of cell 
proliferation, through the use of growth media with reduced serum concentration (2-5% 
serum compared to 10% (data not shown)). 
 
Interestingly, the antiproliferative effect was most pronounced in the ERα positive cell 
lines, MCF-7 and T47D, which lead us to investigate the role of ERα further. Using 
charcoal stripped media, thus removing endogenous hormones and growth factors, we 
had a model system where we could control the growth of oestradiol responsive MCF-7 
cells. By adding oestradiol in increasing concentrations, proliferation increased in a 
dose-dependent manner. However, when co-treating the cells with GW3965, the 
oestradiol-induced proliferation was significantly reduced. In addition, following 
addition of a synthetic ERα antagonist to block ER-dependent proliferation, the 
antiproliferative effect of the LXR agonist in MCF-7 cells was eliminated. Also, 
investigation of the gene expression profiles of MCF-7 cells after T0901317 and 
GW3965 treatment, showed that ERα was reduced both at mRNA and protein levels. 
Together, all this data indicates that LXR induced cell arrest involves an ERα-
dependent pathway. 
 
Even though the antiproliferative effect of LXR was most pronounced in ERα positive 
cells, both GW3965 and T091317 caused to a significant reduction of proliferation also 
in the two remaining, ERα negative cell lines. We therefore concluded that the 
antiproliferative effect of LXR activation must engage several pathways. One possible 
factor was the role of LXRs as regulators of lipid homeostasis. We tested this 
hypothesis using siRNA technology, knocking down SREBP1c, a key target of LXRs 
responsible for regulating genes required for de novo lipogenesis. Reduced levels of 
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SREBP1c lead to reduced rate of proliferation of MCF-7 cells, in agreement with the 
link between lipid biosynthesis and proliferation. However, there was no changes in the 
antiproliferative effect of LXR activation following knock down of SREBP1c, 
indicating that SREBP1c activation and resulting lipogenesis were not involved in LXR 
effects on proliferation of MCF-7 cells. 
 
By further investigating the effects of LXR activation on MCF-7 cellular proliferation, 
we found alterations of expression of genes involved in cell cycle regulation. Treatment 
with GW3965 or T0901317 reduced expression of mRNA and protein levels of Skp2, 
though no increase of p27 protein levels was seen. Cyclin D1 and A2 levels were also 
decreased upon LXR activation, whereas the levels and activity of tumour suppressor 
protein p53 protein were increased. RB protein levels remained the same after LXR 
activation, but became hypophosphorylated, a state of RB that inhibits the cell cycle 
transition from G1 to S phase. 
 
 
4.2 PAPER II: LIVER X RECEPTOR LIGANDS DISRUPT BREAST 
CANCER CELL PROLIFERATION THROUGH AN E2F-MEDIATED 
MECHANISM 
 
The aim of Paper II was to further investigate the effects of LXR activation on breast 
cancer cell lines, as observed in Paper I, by microarray analysis of gene expression. In 
addition, we also wanted to compare any differentially expressed genes in the cell lines 
to disease parameters and survival outcome from cancer patient databases. 
 
We performed microarray analysis of gene expression in the four cell lines from Paper 
I; MCF-7 and T47D, both expressing ERα, and ERα negative cell lines SK-BR-3 and 
MDA-MB-231, treated with synthetic LXR agonist GW3965 or vehicle under the same 
conditions as in Paper I. Differential expression after GW3965 treatment could be seen 
for a total of 2800 genes. MCF-7 cells showed the highest number of changed genes, 
2021, while 462 genes were differentially expressed in T47D cells. ERα transcripts 
were reduced in both cell lines after LXR activation, consistent whith what we saw in 
Paper I. In ERα negative SK-BR-3 cells 603 genes where changed after agonist 
treatment, whereas 926 genes were altered in the triple negative MDA-MB-231 cells. 
In total, 83 genes were differentially regulated in all four cell lines after treatment with 
GW3965; off these 23 were upregulated and 60 downregulated. 
 
We continued by performing gene ontology (GO) analysis on the 83 induced genes that 
were common between the four cell lines, in order to find which biological processes 
were involved in the common response to LXR activation. Among the 23 upregulated 
genes, GO terms for known LXR functions, such as lipid and cholesterol transport, and 
metabolism, were enriched. In contrast, and perhaps more interesting, the 
downregulated gene set, was enriched for GO terms involved in cell cycle regulation, 
DNA replication and other processes associated with cell proliferation.  
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In order to find known transcription factor binding site motifs, we used the 
downregulated gene set and performed a transcription factor binding site analysis of the 
promoter regions of the selected genes. Only one sequence motif enriched in this gene 
set was found, namely the E2F family of transcription factors, enriched in 15 of the 60 
genes. The downregulation of the majority of these 15 genes after GW3965 treatment 
was confirmed with qPCR analysis in all four cell lines. The E2F family includes nine 
members, all involved in cell cycle regulation, and by going back to the 60 commonly 
downregulated genes, E2F2 was found to be responsive to LXR agonist treatment. 
E2F2, together with two other E2F members, E2F1 and E2F3a, are cell cycle promoters 
expressed in late G1 phase of the cell cycle and interact with G1/S checkpoint regulator 
RB.  
 
The reduced expression of this new cell cycle target for LXR activation, E2F2, was 
confirmed at the mRNA level with the most pronounced regulation in the ERα positive 
cell lines, but also, to at a lesser extent, in MDA-MB-231 cells. To investigate the role 
of E2F2 in breast cancer cell lines, E2F2 was knocked down, using siRNA technology, 
in MCF-7, T47D and MDA-MB-231 cells. The knockdown lead to reduced cell 
proliferation in MCF-7 and T47D cells, compared to control cells transfected with 
unspecific siRNA, as measured by absolute number of viable cells,. However, no 
antiproliferative effect of the siRNA knockdown of E2F2 could be seen in the ERα 
negative MDA-MB-231 cells. These cells showed clear reduction of E2F2 mRNA 
expression, but no significant changes in E2F2 protein levels after 48h possibly 
explaining the unchanged proliferation rate. In addition, the differences between the 
ERα positive and negative cell lines were further highlighted when examining E2F 
target gene expression in MCF-7 and MDA-MB-231 cells. 13 out of the 15 examined 
genes were downregulated in MCF-7 cells, while only 5 out of 15 were changed in 
MDA-MB-231 cells. Of the other members of the E2F family, E2F7 was 
downregulated in MCF-7 and T47D cells, while in MDA-MB-231 cells E2F5 was 
upregulated after GW3965 treatment. 
  
To determine the clinical relevance of the 83 genes found to be differentially regulated 
in all four breast cancer cell lines, the expression of these genes was examined in 
expression data from 258 breast cancer patients from Uppsala, Sweden, previously 
described by Miller et al. [205]. Hierarchical clustering of breast cancer patients based 
on the expression profiles of the 60 genes commonly down-regulated after LXR 
activation showed a strong association of these genes with patient survival. Particularly, 
a better outcome could be seen in patients with lower expression levels of the down-
regulated genes, corresponding to the effect of GW3965 treatment, compared to the 
group with higher expression of these genes.  
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4.3 PAPER III: THE OXYSTEROL RECEPTORS LXRα AND LXRβ 
SUPPRESS PROLIFERATION IN THE COLON 
 
Having observed that LXR activation is antiproliferative in various cell types, shown 
by us and others, we aimed with this study to examine the antiproliferative role of 
LXRs in colon cancer cells. We further wanted to make use of LXR deficient mice, 
produced previously in the lab [58], to determine the in vivo role of LXRs in the colon.  
 
Two different human colorectal carcinoma cell lines, Colo205 and HCT116, were used 
in this study. Both expressed LXRα and LXRβ, although LXRα mRNA expression 
was significantly higher in both cell lines and Colo205 had overall higher expression of 
both isoforms. Colo205 and HCT116 also showed functional LXR pathways, with 
induction of classical LXR target genes upon activation with synthetic LXR agonist 
GW3965. 
 
LXR activation with GW3965 lead to a dose dependent reduction of proliferation, 
measured both by flow cytometry and absolute cell number, in Colo205 and HCT116 
cells. In agreement with our previous data from the breast cancer cell lines, LXR 
activation seemed to lead to an arrest of the cells in G1 and G0 phases, with no changes 
of cell viability, checked by trypan blue staining. The antiproliferative effect could be 
further boosted by decreasing the serum concentration in the cell growth media, also 
something we discovered when studying breast cancer cell lines (see Paper I). In the 
subsequent experiments, we therefore continued to use 1% serum in the treatment 
media.  
 
To investigate the role of the two different LXR isoforms, a lentiviral shRNA system 
was used in the Colo205 cells to generate monoclonal cell lines with knockdown of 
either LXRα (shLXRα) or LXRβ (shLXRβ). A nonspecific shRNA was used as 
control. By knocking down any of the isoforms, the amount of cells in G1 and G0 
phases decreased, showing that both LXRα and LXRβ control cell proliferation in 
Colo205 cells. However, the effect was more pronounced, and could be seen at an 
earlier time point, in shLXRβ cells. We continued by treating the cells with GW3965, 
and once again, the antiproliferative effect of LXR activation could be seen in both 
knockdown cell types, but the effect was reduced in shLXRβ cells compared to 
shLXRα and control cells.  
 
To determine the mechanism behind the effect of LXR activation, expression levels of 
several cell cycle regulators were determined. We observed altered expression of key 
players in the G1 to S phase transition; CDK4, cyclin E and CDK2 were downregulated 
at mRNA and/or protein levels, CKI p15 was upregulated and RB protein showed both 
a reduction of total protein level and a hypophosphorylated status, all consistent with an 
arrest at the G1/S checkpoint. However, no reduction could be seen on levels of cyclin 
D1 and CDK4 protein levels. Other changes observed include downregulation of cyclin 
B1 and CDK1, involved in G2 to M phase of the cell cycle, as well as, as seen in Paper 
I, a downregulation of Skp2 at both protein and mRNA levels. When examining the 
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LXR knockdown cells, LXRβ again appeared to have a more pronounced 
antiproliferative role than LXRα, since shLXRβ cells had a reduced suppression at 
mRNA level of the cell cycle genes mentioned above. This was especially clear when 
checking Skp2 protein levels, where the GW3965 induced reduction was abolished in 
shLXRβ cells. In addition, the shLXRβ cells had a higher basal protein level of Skp2 
compared to shLXRα and control cells. 
 
Continuing in vivo, we examined the colon of wild type (WT), LXRα-/-, LXRβ-/- and 
LXRαβ-/- mice. No differences in colon structure could be seen between the different 
groups. We continued by investigating the proliferation of the epithelial cells in the 
crypt of the colon by using immunohistochemistry and staining for proliferation marker 
Ki67, as well as first pulsing the mice with BrdU and then staining for BrdU positive 
cells. We found, using both methods, that LXRαβ-/- mice had a significantly higher 
number of proliferating cells in the crypts of the colon compared to WT controls. No 
differences could be seen in crypt length between the groups, instead the proliferating 
zone seemed to extend higher up in the crypt of LXRαβ-/- mice. No significant changes 
were seen in basal proliferation in LXRα-/- or LXRβ-/- compared to WT animals. 
 
To further confirm the antiproliferative role of LXRs in the colon, WT animals were 
treated for 13 days with GW3965. Compared to controls treated with vehicle, GW3965 
treated animals showed a significant reduction of proliferating cells in the colonic 
crypts. Short term treatment, for 3 days, did not show any significant changes in 
proliferation, although there was a trend toward reduced proliferation in WT and 
LXRα-/- mice, but not in LXRβ-/- mice. Short term GW3965 treatment induced mRNA 
expression of classical LXR target genes in WT mice. This induction was reduced in 
LXRα-/- mice and gone in LXRβ-/- mice. No changes could be seen in Skp2 mRNA 
expression after GW3965 treatment, however interestingly, LXRβ-/- mice had increased 
basal level of Skp2 compared to WT mice, consistent with what we found in shLXRβ 
Colo205 cells. 
 
 
4.4 PAPER IV: THE OXYSTEROL RECEPTORS, LXRα AND LXRβ, 
PROTECT AGAINST DSS- AND TNBS-INDUCED COLITIS IN MICE 
 
Given the fact that inflammatory bowel disease (IBD), including Crohn’s disease and 
ulcerative colitis, is closely connected to CRC, and the anti-inflammatory role of LXRs 
have emerged during recent years, it is interesting to investigate the role of LXRs in the 
colon during IBD, and more specifically colitis.  
 
In order to study the role of LXRs in colitis in vivo, we used two different mouse 
models to induce colitis in wild type (WT) and LXR deficient (LXRα-/-, LXRβ-/- and 
LXRαβ-/-) mice. The first model took advantage of the toxicity of dextran sulphate 
sodium polymers (DSS) on gut epithelial cells. DSS added to the drinking water 
induces acute colitis characterized by bloody diarrhoea, ulcerations and inflammatory 
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infiltration of the colon, first showed in mice by Okayasu et al. [206]. In the second 
complementary model we used intrarectal administration of inflammatory agent 2,4,6-
trinitrobenzenesulfonic acid, TNBS [207, 208]. To monitor the progress of 
inflammation certain clinical symptoms were observed throughout the study, such as 
body weight, and appearance of diarrhoea and rectal bleeding. 
 
Using the DSS model for colitis, we investigated both the effect of LXR activation with 
synthetic LXR agonist GW3965 and the effect on inflammation in LXR deficient mice 
compared to WT controls. WT mice were pre-treated with GW3965 or vehicle by 
gavage for four days, thereafter DSS was added to the drinking water to both WT and 
LXR KO mice for seven to nine days. At day nine, the WT mice on DSS treatment had 
lost 13% of their body weight, and a slight, but significant, protective effect of the 
GW3965 treatment could be seen. The LXR deficient mice had an earlier reduction of 
body weight, and at day seven the LXRαβ-/-, LXRα-/- and LXRβ-/- mice had lost 15%, 
2%, and 14% respectively, compared to a 5% reduction of body weight of WT mice at 
day seven.  
 
The more severe phenotype after DSS treatment seen in LXRαβ-/- and LXRβ-/- mice, 
compared to WT and LXRα-/- mice, was further supported by additional clinical data. 
These mice showed an earlier onset as well as increased scoring, done by manual 
inspection, of both diarrhoea and rectal bleeding. In addition, all animals showed 
reduced colon length after DSS treatment, and this effect was more pronounced in 
LXRαβ-/- and LXRβ-/- mice. Using the TNBS model, we could further support the more 
severe effect of DSS treatment in LXRαβ-/- and LXRβ-/- mice compared to WT mice; 
LXRα-/- mice showed an intermediate phenotype. 
 
Histopathological examination of the colon from all groups showed that DSS treatment 
induced severe ulceration, disruption of crypt structure and hyperplasia. Even though 
these effects were apparent in all groups, they were more pronounced in LXRαβ-/- and 
LXRβ-/- mice, consistent with previous observations. DSS treatment also caused an 
increased accumulation of neutrophile granulocytes and macrophages in the colon, as 
examined with immunohistochemistry. The infiltration of macrophages was also 
increased in LXRαβ-/- mice under basal conditions, compared to WT controls. 
 
We continued investigating if LXRs might have a role in weight recovery after DSS 
induced colitis. The mice were given DSS in the drinking water until they reached 
approximately 10% weight reduction, thereafter the DSS was removed and the body 
weight continued to be monitored. WT mice, both treated with vehicle and GW3965, 
continued to lose weight for about three more days before recovering, while LXRαβ-/- 
mice continued to lose weight for about six days before beginning to recoup. The WT 
mice treated with GW3965 showed a clear trend to recover faster, a statistical 
significant change when compared to LXRαβ-/- mice. Due to ethical considerations, a 
cut off point was introduced at which point the mice were euthanised to prevent 
unnecessary suffering. When comparing the survival rate between the groups, it was 
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also evident that LXRαβ-/- mice recovered less efficiently while WT mice on GW 
treatment recovered faster. In addition, WT mice treated with GW3965 had 
significantly lower immune response compared to controls after DSS treatment, shown 
by lower mRNA expression of several known proinflammatory genes. 
 
To further study the inflammatory effects of LXR activation, we used a human 
colorectal adenocarcinoma cell line, Colo205, pretreated with GW3965 and stimulated 
with TNFα to induce an inflammatory response. Interestingly, LXR activation 
suppressed the inflammatory response of TNFα stimulation, as judged from mRNA 
expression of several inflammatory markers. These results were confirmed in a second 
human colorectal cell line, SW480, using lipopolysaccharide (LPS) or TNFα to 
stimulate an inflammatory response. Using siRNA technology to knock down LXRβ in 
SW480 cells, we could show that the anti-inflammatory effect of LXR activation was 
abolished, suggesting LXRβ to be the most anti-inflammatory LXR isoform in these 
cells. 
 
We then continued our studies by going back in vivo and inducing an inflammatory 
response in the mice by intraperitoneal injections of LPS. LPS, an endotoxin from 
gram-negative bacteria, induces a milder inflammatory response compared to DSS or 
TNBS, thus preventing unnecessary suffering of the animals. We found a stronger 
repression of inflammatory genes after GW3965 treatment in the colon from LXRα-/- 
mice compared to LXRαβ-/- and LXRβ-/- mice, suggesting LXRβ to have a more 
protective role than LXRα against LPS-induced inflammation. In addition, we found 
that LXRαβ-/- mice have a longer response to a single inflammatory stimulus by LPS 
compared to WT mice, with higher mRNA expression of several inflammatory 
mediators and a larger number of infiltrating CD11+ macrophages. 
 
To connect our results back to inflammation and IBD in humans, we compared the 
mRNA expression of LXRα and LXRβ in inflamed colon from patients suffering from 
Crohn’s disease or ulcerative colitis with non-inflamed colon from matched healthy 
individuals. We found that the expression of both LXR isoforms was significantly 
suppressed in patients with IBD compared to healthy controls. 
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5 DISCUSSION 
 
In Paper I we showed a strong antiproliferative effect in four different human breast 
cancer cell lines upon LXR activation with GW3965. In this paper we further 
demonstrated that the antiproliferative effect did not occur via changes in SREBP1c 
expression and lipogenesis. Instead we demonstrated changes in several cell cycle 
regulators. GW3965 activation of LXRs in MCF7 cells reduced mRNA and/or protein 
expression of Skp2, cyclin A2 and cyclin D1. However, in spite the clear changes of 
Skp2 levels, we could not see any indications of stabilisation and increased protein 
levels of the Skp2 target p27. Later studies, especially by Pascual-García et al. [175], 
also showed antiproliferative effects of LXR activation with changes in Skp2 levels 
without involving p27. The difference in p27 regulation might be due to the use of 
different synthetic agonists, GW3965 versus T0901317, different doses, or maybe cell 
lines.  
 
We showed that GW3965 activation of LXR leads to an accumulation of cells in G1 
and G0 phases of the cell cycle. In addition, we also observed a reduction of cyclin D1 
levels and hypophosphorylation of RB. Together this suggests an arrest at the G1/S 
checkpoint of the cell cycle after LXR activation. This is in line with general 
antiproliferative effects of LXR activation now seen in a vast array of cell lines. Our 
results also correlate with what has been shown by others using T0901317 in human 
breast cancer cell lines [167, 180], as well as when activating LXR in a xenograft 
mouse model [197]. 
 
In this first paper, we also show other effects of GW3965 treatment in MCF7 cells.  
LXR activation leads to both increased protein levels and increased activity of tumour 
suppressor p53. In addition, ERα mRNA and protein levels were suppressed upon 
GW3965 treatment. The changes in ERα levels may be one mechanism behind the cell 
cycle arrest seen in ERα positive cells, but other pathways need to be considered to 
explain the effects seen in ERα negative cell lines. We saw no indications that the LXR 
activation increased apoptosis in these cells (data not shown), something that has been 
reported in MCF7 cells [209, 210]. The big difference between our study and the later 
study by El Roz et al. is that we used GW3965, while they used T0901317, the 
endogenous ligand 22(R)-HC or conjugated linoleic acids (CLA). These three latter 
LXR agonists have the potential to modulate other NRs as well. The difference might 
therefore be both ligand-specific and dose-dependent. 
 
Paper II is a follow up study of Paper I, where we continued working with the same 
breast cancer cell lines treated with LXR agonist GW3965. Microarray analysis 
revealed both cell line specific and common LXR target genes. When comparing the 
common downregulated gene set, which was annotated to processes in cell cycle 
regulation and proliferation, with breast cancer tumour samples and patient data we 
found an interesting connection. Patients with tumours expressing lower levels of these 
LXR target genes had better survival compared to patients with a higher expression of 
 36 
these genes. In association with disease outcome, the two clusters also varied in ERα 
and PR expression, as well as lymph node status and tumour grade. This suggests that 
LXR activation, leading to a downregulation of the genes in question, resulted in the 
same gene expression profile as patients with better disease outcome.  
 
The second key finding in Paper II was the identification of the family of E2F 
transcription factors as mediators of the antiproliferative effect of LXR activation. This 
correlates well with the proposed G1 to S transition cell cycle arrest and 
hypophosphorylation of RB, which will sequester members of this family. The E2F 
family is very important for regulation of S phase gene expression, as reported by 
Blaschke et al., especially for E2F1 in VSMC [66]. They showed that LXR activation 
suppresses expression of MCM6, an E2F target gene [211], as well as that E2F1 
overexpression in coronary artery smooth muscle cells (CASMCs) abrogated the LXR 
induced cell cycle arrest. 
 
In our study, E2F2 was the only E2F family member that was differentially regulated in 
all four cell lines after LXR activation. However, there were also changes in some of 
the other E2Fs. Interestingly, both E2F1, as reported by Blaschke et al. [66], and E2F2, 
belong to the E2F activators that are maximally expressed in late G1 phase. The role of 
E2F2 and other E2F family members in the antiproliferative effects of LXR needs to be 
investigated further, as well as if E2F2 is regulated directly or indirectly by LXR 
activation. 
 
Further highlighting the role of LXRs as regulators of cell proliferation, we showed in 
Paper III that activation of LXRs with GW3965 decreased proliferation in human 
colon cell lines. Interestingly, LXR deficient mice had increased expression of 
proliferation markers in the colonic crypts. Uno et al. previously showed that T0901317 
inhibited proliferation in HCT116 human colon cancer cells by modulating the Wnt/β-
catenin signalling pathway [178]. We could not see changes in β-catenin expression in 
the CRC cell lines after GW3965 treatment, nor in vivo when comparing the colon from 
WT and LXRαβ-/- mice. Our data therefore suggests that the antiproliferative LXR 
effects that we report are independent from β-catenin. However, additional experiments 
are needed to fully understand the effects on Wnt signalling. 
 
Consistent with our findings, and with what has been reported by others, the LXR 
activation in the human colon cancer cell lines results in a cell cycle arrest in the G1 to 
S phase transition. We also demonstrated hypophosphorylation of RB, decreased 
expression of Skp2, as well as changes in other cell cycle regulators. Cell cycle 
promoters such as CDK1, CDK2, CDK4, cyclin E, cyclin B1 and c-myc were all 
downregulated, while PKI p15 expression was upregulated. Cyclin B1 and CDK1 are 
involved in later stages of the cell cycle, but these changes might be secondary and due 
to the cell cycle arrest. 
 
Studying proliferation in colon cells also gave us the possibility to examine basal 
proliferation in vivo in WT and LXR deficient mice. We found that LXRαβ-/- mice had 
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an increased proliferation in the colonic crypt compared to WT mice. Also, activation 
of LXRs with GW3965 reduced proliferation in the colonic crypt of WT animals. Our 
results clearly show an in vivo antiproliferative effect of LXR activation in the colon. 
This has recently been supported by an extensive study from Lo Sasso et al. where they 
demonstrate that both GW3965 and LXRα specific activation reduced proliferation in 
human colon cancer cell lines [173].  In addition, they showed that intestinal specific 
LXRα activation in vivo in mice reduced tumour growth and induced apoptosis in a 
xenograft model, and resulted in fewer and smaller tumours in two different mouse 
cancer models. They further showed the importance of lipid and cholesterol 
metabolism as a factor in LXR-mediated antiproliferative events in CRC. Microarray 
experiments comparing tumours from the colon, ileum and xenografts from mice 
overexpressing LXRα with control tumours identified several LXR target genes 
annotated to metabolism that have previously been associated with the antiproliferative 
effect of LXRs.   
 
With Paper IV we took a step away from direct regulation of proliferation by LXRs, 
and investigated one of the major risk factors behind CRC, namely inflammatory bowel 
disease, IBD. Using two different mouse models of colitis, DSS- and TNBS-induced 
colitis, we showed that activation of LXRs dampens the inflammatory response by 
downregulating pro-inflammatory mediators. LXR deficient mice had a faster and more 
severe disease progression, and recovered more slowly when the inflammatory agent 
was removed. This suggests that LXRs have a protective role in IBD.  
 
We further demonstrated expression of LXR regulated genes is suppressed in colon 
samples from patients with either Crohn’s disease or ulcerative colitis compared to 
healthy colon, supporting the role of LXRs as anti-inflammatory mediators in the colon. 
Together, the data in Paper IV suggests the potential for LXR mediated inhibition of 
inflammation during IBD, reducing the risk for developing CRC. 
 
In summary, our studies have strengthened the view of LXRs as modulators of cell 
proliferation. Activation of LXRs leads to a G1/G0 cell cycle arrest by regulation of key 
players in the cell cycle. Other reported mechanisms behind the antiproliferative effect 
of LXR activation include regulation of cholesterol homeostasis, depriving the fast 
growing tumour cells vital nutrients, and induction of apoptosis.  
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6 CONCLUDING REMARKS 
 
The antiproliferative effects of LXRs make them potential targets in cancer therapy, 
however, many questions still remain. LXRs, like many other NRs, are favourable drug 
targets since their activity is regulated by small molecular compounds that can 
relatively easily be delivered. The biggest caveat, so far, in using LXR ligands as 
therapeutic agents has been the increase of lipogenesis in the liver leading to 
hypertriglyceridemia and increasing the risk for cardiovascular disease. Finding new 
ligands in the form of subtype-, tissue- or pathway specific agonists, may be one 
solution. However, in mortal diseases, such as many cancers, the increased risks 
associated with induced hepatic lipogenesis could be considered acceptable, if it means 
a prolongation of life.  
 
Many chronic inflammatory conditions are associated with a significant increased risk 
of developing cancer, as with CRC and IBD. On one side, using LXR agonists to treat 
these inflammatory diseases would also, indirectly, reduce the development of certain 
cancers. On the other side, activating LXRs could disrupt a proper immune response 
towards the developing tumour via DCs and their migration of lymph nodes and 
thereby providing an opportunity for the tumour to escape immune surveillance. 
 
An additional point to consider is that much of the published data on LXR activation is 
performed using the synthetic LXR agonist T0901317. It has been shown that 
T0901317 can activate other NRs, specifically FXR [36], PXR [37] and RORs [38]. 
The LXR effect observed in studies where the T0901317 effect has not been shown to 
be abolished with LXR deficient systems, such as LXR deficient mice or siRNA in cell 
lines, remains unvalidated and should be confirmed using the GW3965 agonist.  
 
This thesis has focused on the antiproliferative role of LXRs after activation with 
synthetic agonists. However, studies have also shown that endogenous LXR ligands 
[212], phytosterols ([213], also reviewed in [214] and [215]) and other ligands from 
plants  [210, 213] may regulate proliferation and/or induce apoptosis in a variety of cell 
lines and cancer models, possibly via the LXRs. This connects the LXRs to dietary 
factors for increased or decreased cancer risk. For instance, there might be a link 
between a diet rich in phytosterols and phytostanols, protection against CRC and 
LXRs, giving these NRs a role in prevention of cancer and not only as a target for 
cancer therapy. 
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